| P50 | author | Claudiu T Supuran | Q28211545 |
| | Igor Almeida Rodrigues | Q40311078 |
| | Alane Beatriz Vermelho | Q59821891 |
| P2093 | author name string | Alcino Palermo de Aguiar | |
| | Claudia Magalhães Calvet | |
| | Dayanne da Rocha de Menezes | |
| | Igor Rodrigues Almeida | |
| | Mirian Claudia de Souza Pereira | |
| P2860 | cites work | Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection | Q24645720 |
| | Novel amidines and analogues as promising agents against intracellular parasites: a systematic review | Q26825025 |
| | Trypanosoma cruzi response to sterol biosynthesis inhibitors: morphophysiological alterations leading to cell death | Q28485411 |
| | Neglected parasitic infections in the United States: Chagas disease | Q33588466 |
| | A nonazole CYP51 inhibitor cures Chagas' disease in a mouse model of acute infection | Q33876638 |
| | A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi. | Q34228426 |
| | Calpains: potential targets for alternative chemotherapeutic intervention against human pathogenic trypanosomatids | Q34272471 |
| | American trypanosomiasis (Chagas disease). | Q34277333 |
| | Economic crisis and increased immigrant mobility: new challenges in managing Chagas disease in Europe | Q34399329 |
| | Proteinases of Trypanosoma cruzi: patential targets for the chemotherapy of Changas desease | Q34780286 |
| | Antagonic activities of Trypanosoma cruzi metacaspases affect the balance between cell proliferation, death and differentiation | Q36084477 |
| | Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. | Q36505372 |
| | Heart failure in South America | Q36928523 |
| | Accelerating the development of a therapeutic vaccine for human Chagas disease: rationale and prospects | Q37286061 |
| | Aspartic peptidases of human pathogenic trypanosomatids: perspectives and trends for chemotherapy. | Q37334816 |
| | Reversible cysteine protease inhibitors show promise for a Chagas disease cure | Q37544765 |
| | Cruzain : the path from target validation to the clinic | Q37887591 |
| | Epidemiology of Chagas disease in Europe: many calculations, little knowledge | Q38132635 |
| | Carbonic anhydrase inhibitors drug design | Q38154557 |
| | Chagas disease: the challenge of polyparasitism? | Q38192158 |
| | Therapeutical approaches under investigation for treatment of Chagas disease | Q38214136 |
| | Rational drug design paradigms: the odyssey for designing better drugs. | Q38369435 |
| | Design, synthesis, and evaluation of hydroxamic acid derivatives as promising agents for the management of Chagas disease. | Q39050394 |
| | Detection of matrix metallopeptidase-9-like proteins in Trypanosoma cruzi | Q39902784 |
| | Biological, ultrastructural effect and subcellular localization of aromatic diamidines in Trypanosoma cruzi | Q39945921 |
| | Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. | Q42215365 |
| | Evaluation of benznidazole treatment combined with nifurtimox, posaconazole or AmBisome® in mice infected with Trypanosoma cruzi strains | Q44520752 |
| | Effects of a marine serine protease inhibitor on viability and morphology of Trypanosoma cruzi, the agent of Chagas disease | Q44722468 |
| | Cloning, Characterization, and Sulfonamide and Thiol Inhibition Studies of an α-Carbonic Anhydrase from Trypanosoma cruzi, the Causative Agent of Chagas Disease | Q58863183 |
| P433 | issue | 6 | |
| P921 | main subject | Chagas disease | Q649558 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 964-973 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Journal of Enzyme Inhibition and Medicinal Chemistry | Q15708877 |
| P1476 | title | Hydroxamic acid derivatives: a promising scaffold for rational compound optimization in Chagas disease | |
| P478 | volume | 31 | |